High Expression of Long Noncoding RNA HOTAIRM1 is Associated with the Proliferation and Migration in Pancreatic Ductal Adenocarcinoma

  • Yongyun Luo
  • Yaqin He
  • Xiaoping Ye
  • Jianjun Song
  • Qi Wang
  • Yukui LiEmail author
  • Xiaoliang XieEmail author
Original Article


Pancreatic ductal adenocarcinoma (PDAC) is an incurable malignancy. Long noncoding RNA (LncRNA) HOTAIRM1 (HOX antisense intergenic RNA myeloid 1) has been shown to play important roles in the progression of several type cancers. However, the exact role of HOTAIRM1 in PDAC development remains largely unknown. This study aims to evaluate the potential function of HOTAIRM1 in the development and progress of PDAC. HOTAIRM1 expression was measured by RT-qPCR in forty seven paired human PDAC tissues and five PDAC cell lines. SW1990 and PANC-1 cells were transfected with siHOTAIRM1 to achieve HOTAIRM1 silence. MTT assay and colony formation assay were used to detect the effect of HOTAIRM1 knockdown on cell proliferation. The impact of HOTAIRM1 silence on cell cycle and apoptosis was assessed by flow cytometry assay. Transwell migration assay was performed to explore the influence of HOTAIRM1 downregulation on the migratory potential of PDAC cells. Western blot assay was applied to determine the expression changes of cell cycle, apoptosis, and migration-related genes before and after downregulating HOTAIRM1. HOTAIRM1 expression was abnormally upregulated in PDAC tissues and cells when compared with the control samples, and was positively associated with the expression of KRAS gene mutation. In vitro functional experiments, HOTAIRM1 expression was significantly downregulated by transfection with siHOTAIRM1 in SW1990 and PANC cell lines. HOTAIRM1 knockdown attenuated cell proliferation by inducing cell cycle arrest at G0/G1 phase, promoted cell apoptosis, and inhibited cell migration in PDAC cells by regulating related-genes expression. In conclusion, HOTAIRM1 plays a critical role in PDAC progression, which may be a novel diagnostic and rational therapeutic target for the treatment of pancreatic ductal adenocarcinoma.


HOTAIRM1 Pancreatic ductal adenocarcinoma Proliferation Migration 



This study was supported by National Natural Science Foundation of China (Grant No.: 81460152) and Ningxia Medical University Scientific Research Project (Grant No.: XY201823).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Oncology TL (2014) Pancreatic cancer in the spotlight. Lancet Oncol 15:241CrossRefGoogle Scholar
  2. 2.
    Taher MA, Khan ZR, Chowdhury MM, Nureelahi M, Chowdhury AK, Faruque MS, Wahiduzzaman M, Haque MA (2015) Pylorus preserving pancreaticoduodenectomy vs. standard Whipple's procedure in case of carcinoma head of the pancreas and periampullary carcinoma. Mymensingh Med J 24:319–325Google Scholar
  3. 3.
    Xu YF, Lu Y, Cheng H, Jiang J, Xu J, Long J, Liu L, Ni Q, Liu C, Yu XJ (2015) High expression of human leukocyte antigen-G is associated with a poor prognosis in patients with PDAC. Curr Mol Med 15:360–367CrossRefGoogle Scholar
  4. 4.
    Ma J, Jemal A (2013) The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend? Future Oncol 9:917–919CrossRefGoogle Scholar
  5. 5.
    Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10:155–159CrossRefGoogle Scholar
  6. 6.
    Ponting CP, Oliver PL, Reik W (2009) Evolution and functions of long noncoding RNAs. Cell 136:629–641CrossRefGoogle Scholar
  7. 7.
    Léveillé N, Melo CA, Rooijers K, Díazlagares A, Melo SA, Korkmaz G, Lopes R, Akbari MF, Maia AR, Wijchers PJ (2015) Genome-wide profiling of p53-regulated enhancer RNAs uncovers a subset of enhancers controlled by a lncRNA. Nat Commun 6:6520CrossRefGoogle Scholar
  8. 8.
    Yin Y, Yan P, Lu J, Song G, Zhu Y, Li Z, Zhao Y, Shen B, Huang X, Zhu H (2015) Opposing roles for the lncRNA haunt and its genomic locus in regulating HOXA gene activation during embryonic stem cell differentiation. Cell Stem Cell 16:504–516CrossRefGoogle Scholar
  9. 9.
    Wapinski O, Chang HY (2011) Long noncoding RNAs and human disease. Trends Cell Biol 21:354–361CrossRefGoogle Scholar
  10. 10.
    Gong C, Maquat LE (2011) lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. Nature 470:284–288CrossRefGoogle Scholar
  11. 11.
    Crea F, Watahiki A, Quagliata L, Xue H, Pikor L, Parolia A, Wang Y, Lin D, Wan LL, Farrar WL (2014) Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 5:764CrossRefGoogle Scholar
  12. 12.
    Shi Y, Lu J, Zhou J, Tan X, He Y, Ding J, Tian Y, Wang L, Wang K (2014) Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells. Biochem Biophys Res Commun 446:448–453CrossRefGoogle Scholar
  13. 13.
    Zhuang M, Gao W, Xu J, Wang P, Shu Y (2014) The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. Biochem Biophys Res Commun 448:315–322CrossRefGoogle Scholar
  14. 14.
    Ding YC, Yu W, Ma C, Wang Q, Huang CS, Huang T (2014) Expression of long non-coding RNA LOC285194 and its prognostic significance in human pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol 7:8065–8070Google Scholar
  15. 15.
    Peng W, Gao W, Feng J (2014) Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol 31:346CrossRefGoogle Scholar
  16. 16.
    Jiao F, Hu H, Han T, Yuan C, Wang L, Jin Z, Guo Z, Wang L (2015) Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci 16:6677–6693CrossRefGoogle Scholar
  17. 17.
    Kim K, Jutooru I, Chadalapaka G, Johnson G, Frank J, Burghardt R, Kim S, Safe S (2013) HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32:1616–1625CrossRefGoogle Scholar
  18. 18.
    Zhang X, Lian Z, Padden C, Gerstein MB, Rozowsky J, Snyder M, Gingeras TR, Kapranov P, Weissman SM, Newburger PE (2009) A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster. Blood 113:2526–2534CrossRefGoogle Scholar
  19. 19.
    Zhou Y, Gong B, Jiang ZL, Zhong S, Liu XC, Dong K, Wu HS, Yang HJ, Zhu SK (2015) Microarray expression profile analysis of long non-coding RNAs in pancreatic ductal adenocarcinoma. Int J Oncol 48:670CrossRefGoogle Scholar
  20. 20.
    Marina DB, Salut B, Josep N, Marta P, Anna C, David G, Lourdes E, Mar T, Inmaculada H, Maria RJ (2015) The lincRNAHOTAIRM1, located in theHOXAgenomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Oncotarget 6:31613Google Scholar
  21. 21.
    Chen Y, Wu JJ, Lin XB, Bao Y, Chen ZH, Zhang CR, Cai Z, Zhou JY, Ding MH, Differential WXJ (2015) lncRNA expression profiles in recurrent gliomas compared with primary gliomas identified by microarray analysis. Int J Clin Exp Med 8:5033–5043Google Scholar
  22. 22.
    Kim ST, Lim DH, Jang KT, Lim T, Lee J, Choi YL, Jang HL, Yi JH, Baek KK, Park SH (2011) Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 10:1993–1999CrossRefGoogle Scholar
  23. 23.
    Rasola A, Geuna M (2001) A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry 45:151–157CrossRefGoogle Scholar
  24. 24.
    Yi Z, Shi M, Hao C, Gu J, Zhang J, Shen B, Deng X, Xie J, Xi Z, Peng C (2015) NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells. Oncotarget 6:21443–21451Google Scholar
  25. 25.
    Daniel Z, Yuliya PG, Der CJ, Bryant KL (2016) KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers 8:45CrossRefGoogle Scholar
  26. 26.
    T G and S D (2012) The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol 9:703–719CrossRefGoogle Scholar
  27. 27.
    Wan L, Kong J, Tang J, Wu Y, Xu E, Lai M, Zhang H (2016) HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor. J Cell Mol Med 20:2036–2044CrossRefGoogle Scholar
  28. 28.
    Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D (2014) Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget 5:9864–9876Google Scholar
  29. 29.
    Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA (2015) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 29:595–608Google Scholar
  30. 30.
    Hilgers W, Rosty C, Hahn SA (2002) Molecular pathogenesis of pancreatic cancer. Hematol Oncol Clin North Am 16:17–35CrossRefGoogle Scholar
  31. 31.
    Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7:295–308CrossRefGoogle Scholar
  32. 32.
    Ijichi H, Chytil A, Gorska AE, Aakre ME, Fujitani Y, Fujitani S, Wright CVE, Moses HL (2006) Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-β signaling in cooperation with active Kras expression. Genes Dev 20:3147–3160CrossRefGoogle Scholar
  33. 33.
    Thayer SP, Magliano MPD, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Yan PQ, Gysin S, Castillo CF, Yajnik V (2003) Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851–856CrossRefGoogle Scholar
  34. 34.
    Magliano MPD, Biankin AV, Heiser PW, Cano DA, Gutierrez PJA, Deramaudt T, Segara D, Dawson AC, Kench JG, Henshall SM (2007) Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS One 2:e1155CrossRefGoogle Scholar
  35. 35.
    Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8:979–986CrossRefGoogle Scholar
  36. 36.
    Mikayama Y, Morinaga S, Watanabe T, Numata M, Tamagawa H, Yamamoto N, Shiozawa M, Akaike M, Yoichi K, Matsukuma S (2012) Association of KRAS G12D mutation with outcome in patients with pancreatic cancer after surgery. J Clin Oncol 30:221CrossRefGoogle Scholar
  37. 37.
    Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X (2015) OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine bothin vitroandin vivo. Oncotarget 6:26230–26241Google Scholar
  38. 38.
    Coqueret O (2002) Linking cyclins to transcriptional control. Gene 299:35–55CrossRefGoogle Scholar
  39. 39.
    Aix E, Sánchezferrer C, Aguado T, Flores I (2016) Postnatal telomere dysfunction induces cardiomyocyte cell-cycle arrest through p21 activation. J Cell Biol 213:571–583CrossRefGoogle Scholar
  40. 40.
    Cannell I, Merrick K, Morandell S, Zhu CQ, Braun C, Grant R, Cameron E, Tsao MS, Hemann M, Yaffe M (2015) A pleiotropic RNA-binding protein controls distinct cell cycle checkpoints to drive resistance of p53 -defective tumors to chemotherapy. Cancer Cell 28:623–637CrossRefGoogle Scholar
  41. 41.
    Cully M (2015) Trial watch: Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy. Nat Rev Drug Discov 14:374CrossRefGoogle Scholar
  42. 42.
    Zhang X, Weissman SM, Newburger PE (2014) Long intergenic non-coding RNA HOTAIRM1 regulates cell cycle progression during myeloid maturation in NB4 human promyelocytic leukemia cells. RNA Biol 11:777–787CrossRefGoogle Scholar
  43. 43.
    Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14:159–169CrossRefGoogle Scholar
  44. 44.
    Gartel AL, Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65:3980–3985CrossRefGoogle Scholar
  45. 45.
    JM B, LD A (2005) The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5:231–237CrossRefGoogle Scholar
  46. 46.
    Nollet F, Berx G, Van RF (1999) The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun 2:77–85CrossRefGoogle Scholar
  47. 47.
    Mcinroy L, Määttä A (2007) Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun 360:109–114CrossRefGoogle Scholar
  48. 48.
    Nagi C, Guttman M, Jaffer S, Qiao R, Keren R, Triana A, Li M, Godbold J, Bleiweiss IJ, Hazan RB (2005) N-cadherin expression in breast cancer: correlation with an aggressive histologic variant--invasive micropapillary carcinoma. Breast Cancer Res Treat 94:225–235CrossRefGoogle Scholar
  49. 49.
    Cheng CW, Chang CW, Chu HW, Chen CY, Yu JC, Chao JI, Liu HF, Ding SL, Shen CY (2012) MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer. Breast Cancer Res Treat 134:1081–1093CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2019

Authors and Affiliations

  1. 1.Department of Hepatobiliary SurgeryGeneral Hospital of Ningxia Medical UniversityYinchuanChina
  2. 2.Surgery LaboratoryGeneral Hospital of Ningxia Medical UniversityYinchuanChina
  3. 3.Department of Colorectal SurgeryGeneral Hospital of Ningxia Medical UniversityYinchuanChina
  4. 4.Ningxia Medical UniversityYinchuanChina

Personalised recommendations